�Less than a year into the process, RamSoft, a starring developer of affordable healthcare information technology, has successfully helped PresGar, the nation's largest privately-owned medical imaging service company, establish a significant digital mammography comportment at eight-spot of its imaging centers.
The solution has been increased efficiency among PresGar mammographers and technologists and substantial nest egg for the company. If things go as planned, a one-ninth center may soon join the flux, combining RamSoft's PowerServer PACS and Gateway Routers with PresGar's new digital mammography system.
"It's a home run," Dave Kost, Imaging Informatics Manager for PresGar, said of the integration. "We couldn't be happier."
PresGar, of Tampa, FL, operates 36 imaging centers that complete an estimated 350,000 exams yearly. To facilitate optimal viewing, 10 PowerServer PACS, some serving more than one imaging center, along with three Gateway Routers receive been installed by RamSoft, of Toronto, Ontario, Canada.
The digital effort began in October 2007 when the first new mammography system was integrated with the RamSoft technology. Seven other systems were added through mid-2008, and a ninth system will be implemented afterward this year. The young digital mammography systems, in New York, Virginia, Ohio and Florida, are replacing film-screen mammography units at each center.
"PresGar was really our first big account in terms of establishing our solution as ideal for a distributed outpatient imaging center grouping," said Vijay Ramanathan, President and CEO of RamSoft. "The relationship has allowed us to prove that our solution is superior to anything else in that genial of environment."
In making the move to digital, PresGar had one predominate goal: to enable the capture of superior images that john be manipulated for optimum viewing victimisation the RamSoft mammography module. The PACS facilitates both on-site viewing and transmittance to remote locations for off-site limited review.
Offered in several configurations, the PowerServer provides a reliable, fault-tolerant, web-based approach to PACS, accommodating inexhaustible users and workstations. Features range from study trailing from start to finish and unmated real-time worklist flexibility, to prefetching of current and prior studies and elastic viewing protocols specific to modality and body office. A suite of clinical tools intentional to optimize images and a digital dictation module also are provided.
An important constituent is RamSoft's mammography module, which automatically sorts left wing and right digital image series and matches them to prior films for easy comparing.
"What we've done is make digital mammography function similarly to all of the other modalities offered by PresGar," Ramanathan aforementioned. "That has eliminated the need for them to make a separate, pricy investment in mammography. No longer does a company such as PresGar want to have one solution for all of the modalities and a separate solution for mammography."
In less than a year the RamSoft collaboration already has benefited PresGar. The company saved hundreds of thousands of dollars by opting not to purchase dedicated workstations; film has been eliminated, also delivery PresGar a substantial amount of money; technologists and mammographers ar more efficient, enabling more studies to be realized and revenues to increase; the tone of images captured has been enhanced, increasing reader confidence and minimizing liability; and images can be quickly and easily transmitted to remote locations. Clearly, RamSoft is playing an important theatrical role in PresGar's transition to digital mammography and boilers suit growth.
Numbers underscore that. Between 40 and 50 studies are completed day-after-day at each site compared with 18 to 20 per day a year ago. PresGar's overall efficiency has increased by 30%-40%.
"Digital mammography combined with RamSoft PACS has saved us tens of thousands of dollars beyond the workstation savings, and that's a big deal," Kost aforesaid. "Imaging centers face a very tough climate these days, and we have to do what we can to be efficient and profitable. RamSoft PACS and its Gateway Routers have at rest a long way toward helping us achieve that."
About RamSoft
RamSoft, Inc. is a leading healthcare IT software and services company that is dedicated to creating and delivering award-winning medical imagination and radioscopy solutions to its clients in the U.S. and around the world. The company's goal is to enable tomography facilities, radioscopy centers, ambulatory and acute-care practices to offer a superior floor and quality of patient role care with the affordable and feature-rich PowerServer� Series of PACS, RIS/PACS, teleradiology, and patient information management systems.
RamSoft
More information
Sunday, 7 September 2008
Thursday, 28 August 2008
Ed Sells Home
Former Tonight show buddy Ed McMahon has in agreement to sell his home � and not to Donald Trump!
Howard Bragman, Ed's spokesman, says that a deal has been reached on the California domiciliation � which is in the same neighborhood as Britney Spears' pad � and that Ed will be moving out when the sale is complete.
After Ed defaulted on a $4.8 million loan and faced foreclosure, Donald Trump had offered to buy the house and act as landlord.
We're not sure we'd want our landlord yelling "You're fired!" either.
�
More info
Monday, 18 August 2008
Ardea Biosciences Presents Phase 2a Antiviral Activity Data For Lead HIV Candidate, RDEA806 At XVII International AIDS Conference
�Ardea
Biosciences, Inc. (Nasdaq: RDEA) announced that information was presented
from its completed Phase 2a proof-of-concept monotherapy study of RDEA806,
the Company's novel investigational non-nucleoside reverse transcriptase
inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV),
demonstrating robust antiviral activity with a well-tolerated visibility. An
oral presentation of the data was granted today by Dr. Graeme Moyle, Director
of HIV Research, Chelsea and Westminster Hospital, during a late breaker
session at the XVII International AIDS Conference in Mexico City.
"We are extremely pleased that the last results of the Phase 2a sketch
presented today demonstrate that 800 mg once day-after-day produced like viral
burden reductions as 400 mg twice daily, providing last confirmation that
RDEA806 workings equally well given either once or twice everyday. Based on the
data to date, we continue to consider that RDEA806 has the potential to be a
first-line therapy for the treatment of HIV," aforementioned Barry D. Quart, PharmD,
Ardea's President and CEO. "We look forward to further evaluating RDEA806
and are on track to begin a Phase 2b study comparing once day-to-day doses of
RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients
receiving ground treatment with Truvada(R) (emtricitabine and tenofovir
disoproxil fumarate), in the third quarter of this year. A recently
completed drug interaction study with RDEA806 and Truvada confirmed the
want of drug-drug interactions between these agents, paving the way for
initiation of the Phase 2b written report."
The Phase 2a randomized, double-blind, placebo-controlled trial
evaluated the antiviral agent activity, pharmacokinetics, safety and tolerability
of once- and twice-daily oral dosing regimens of RDEA806 versus placebo in
48 HIV-positive patients who were naive to antiretroviral treatment. Nine
out of 12 patients in each of four cohorts received RDEA806. The primary
efficacy end point was the change from baseline in plasma viral payload.
Results from all tetrad cohorts showed a medial reduction in plasma viral
load at nadir of 1.8 - 2.0 log copies/mL. There were no serious adverse
events, premature discontinuations, clinically relevant ECGs changes or
drug-related rash reported in any age bracket. The incidence of CNS side effects
was like between do drugs and placebo. Gastrointestinal position effects were
most uncouth, but these effects were generally transient and mild.
The presentation is uncommitted on the conference site
(http://www.aids2008.org) and on the Company website
(hypertext transfer protocol://www.ardeabio.com) under the title "Antiviral action of RDEA806, a
novel HIV non-nucleoside reverse rNA polymerase inhibitor, in treatment of
naive HIV patients."
About RDEA806
RDEA806 is a novel non-nucleoside blow transcriptase inhibitor
(NNRTI) for the voltage treatment of HIV infection. Based on preclinical
and clinical studies to-date, we believe that RDEA806 may have important
competitive advantages compared to currently available NNRTIs. These
include the potential for potent antiviral agent activity against a wide range of
HIV viral isolates, including those that are repellent to efavirenz
(Sustiva(R)) and other presently available NNRTIs; a high genetic barrier
to resistance; no reproductive toxicity based on beast studies; the
potential to be administered in a patient-friendly, unwritten dosing regimen;
limited pharmacokinetic interactions with other drugs; and the ability to
be co-formulated with other HIV antiviral agent drugs.
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a ergonomics
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, urarthritis, cancer and inflammatory
diseases. We take four production candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product nominee
is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for
the treatment of patients with HIV. We have evaluated our second-generation
NNRTI for the treatment of HIV, RDEA427, in a human micro-dose
pharmacokinetic study and have selected it for clinical development.
RDEA594, our lead product candidate for the treatment of gout, is in
preclinical development. We are currently evaluating our lead MEK
inhibitor, RDEA119, in a Phase 1 written report in advanced cancer patients and have
completed a Phase 1 study in normal healthy volunteers as a herald to
trials in patients with inflammatory diseases. Lastly, we stimulate evaluated
our second-generation MEK inhibitor for the treatment of genus Cancer and
seditious diseases, RDEA436, in a human micro-dose pharmacokinetic study
and have selected it for clinical development.
Statements contained in this press release regarding matters that are
non historical facts are "innovative statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
dissent materially from those expressed or implied by such forward-looking
statements. Such statements include, simply are non limited to, statements
regarding our goals, including the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the
results of preclinical, clinical and other studies. Risks that contribute
to the uncertain nature of the forward-looking statements include: risks
related to the issue of presymptomatic and clinical studies, risks related
to regulatory approvals, delays in commencement of preclinical and clinical
studies, and costs associated with our do drugs discovery and development
programs and line of work development activities. These and other risks and
uncertainties are described more fully in our most recently filed SEC
documents, including our Annual Report on Form 10-K and our Quarterly
Reports on Form 10-Q, under the headings "Risk Factors." All
advanced statements contained in this press tone ending speak only if as of
the appointment on which they were made. We undertake no obligation to update such
statements to reflect events that come or luck that exist after
the date on which they were made.
Ardea Biosciences, Inc.
http://www.ardeabio.com
View dose information on Sustiva.
More info
Biosciences, Inc. (Nasdaq: RDEA) announced that information was presented
from its completed Phase 2a proof-of-concept monotherapy study of RDEA806,
the Company's novel investigational non-nucleoside reverse transcriptase
inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV),
demonstrating robust antiviral activity with a well-tolerated visibility. An
oral presentation of the data was granted today by Dr. Graeme Moyle, Director
of HIV Research, Chelsea and Westminster Hospital, during a late breaker
session at the XVII International AIDS Conference in Mexico City.
"We are extremely pleased that the last results of the Phase 2a sketch
presented today demonstrate that 800 mg once day-after-day produced like viral
burden reductions as 400 mg twice daily, providing last confirmation that
RDEA806 workings equally well given either once or twice everyday. Based on the
data to date, we continue to consider that RDEA806 has the potential to be a
first-line therapy for the treatment of HIV," aforementioned Barry D. Quart, PharmD,
Ardea's President and CEO. "We look forward to further evaluating RDEA806
and are on track to begin a Phase 2b study comparing once day-to-day doses of
RDEA806 to efavirenz (SUSTIVA(R), Stocrin(R)) in first-line patients
receiving ground treatment with Truvada(R) (emtricitabine and tenofovir
disoproxil fumarate), in the third quarter of this year. A recently
completed drug interaction study with RDEA806 and Truvada confirmed the
want of drug-drug interactions between these agents, paving the way for
initiation of the Phase 2b written report."
The Phase 2a randomized, double-blind, placebo-controlled trial
evaluated the antiviral agent activity, pharmacokinetics, safety and tolerability
of once- and twice-daily oral dosing regimens of RDEA806 versus placebo in
48 HIV-positive patients who were naive to antiretroviral treatment. Nine
out of 12 patients in each of four cohorts received RDEA806. The primary
efficacy end point was the change from baseline in plasma viral payload.
Results from all tetrad cohorts showed a medial reduction in plasma viral
load at nadir of 1.8 - 2.0 log copies/mL. There were no serious adverse
events, premature discontinuations, clinically relevant ECGs changes or
drug-related rash reported in any age bracket. The incidence of CNS side effects
was like between do drugs and placebo. Gastrointestinal position effects were
most uncouth, but these effects were generally transient and mild.
The presentation is uncommitted on the conference site
(http://www.aids2008.org) and on the Company website
(hypertext transfer protocol://www.ardeabio.com) under the title "Antiviral action of RDEA806, a
novel HIV non-nucleoside reverse rNA polymerase inhibitor, in treatment of
naive HIV patients."
About RDEA806
RDEA806 is a novel non-nucleoside blow transcriptase inhibitor
(NNRTI) for the voltage treatment of HIV infection. Based on preclinical
and clinical studies to-date, we believe that RDEA806 may have important
competitive advantages compared to currently available NNRTIs. These
include the potential for potent antiviral agent activity against a wide range of
HIV viral isolates, including those that are repellent to efavirenz
(Sustiva(R)) and other presently available NNRTIs; a high genetic barrier
to resistance; no reproductive toxicity based on beast studies; the
potential to be administered in a patient-friendly, unwritten dosing regimen;
limited pharmacokinetic interactions with other drugs; and the ability to
be co-formulated with other HIV antiviral agent drugs.
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego, California, is a ergonomics
company focused on the discovery and development of small-molecule
therapeutics for the treatment of HIV, urarthritis, cancer and inflammatory
diseases. We take four production candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product nominee
is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for
the treatment of patients with HIV. We have evaluated our second-generation
NNRTI for the treatment of HIV, RDEA427, in a human micro-dose
pharmacokinetic study and have selected it for clinical development.
RDEA594, our lead product candidate for the treatment of gout, is in
preclinical development. We are currently evaluating our lead MEK
inhibitor, RDEA119, in a Phase 1 written report in advanced cancer patients and have
completed a Phase 1 study in normal healthy volunteers as a herald to
trials in patients with inflammatory diseases. Lastly, we stimulate evaluated
our second-generation MEK inhibitor for the treatment of genus Cancer and
seditious diseases, RDEA436, in a human micro-dose pharmacokinetic study
and have selected it for clinical development.
Statements contained in this press release regarding matters that are
non historical facts are "innovative statements" within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
dissent materially from those expressed or implied by such forward-looking
statements. Such statements include, simply are non limited to, statements
regarding our goals, including the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the
results of preclinical, clinical and other studies. Risks that contribute
to the uncertain nature of the forward-looking statements include: risks
related to the issue of presymptomatic and clinical studies, risks related
to regulatory approvals, delays in commencement of preclinical and clinical
studies, and costs associated with our do drugs discovery and development
programs and line of work development activities. These and other risks and
uncertainties are described more fully in our most recently filed SEC
documents, including our Annual Report on Form 10-K and our Quarterly
Reports on Form 10-Q, under the headings "Risk Factors." All
advanced statements contained in this press tone ending speak only if as of
the appointment on which they were made. We undertake no obligation to update such
statements to reflect events that come or luck that exist after
the date on which they were made.
Ardea Biosciences, Inc.
http://www.ardeabio.com
View dose information on Sustiva.
More info
Friday, 8 August 2008
Virtual Audio Project
Artist: Virtual Audio Project
Genre(s):
New Age
Electronic
Discography:
Virtual World
Year:
Tracks: 10
Time
Year:
Tracks: 11
Psychosis
Year:
Tracks: 9
Nightmares
Year:
Tracks: 9
Network
Year:
Tracks: 10
Mind Contact
Year:
Tracks: 14
Metropolis
Year:
Tracks: 10
Love
Year:
Tracks: 12
Legend
Year:
Tracks: 8
Jurassic
Year:
Tracks: 9
Impact
Year:
Tracks: 16
Hypnotic
Year:
Tracks: 11
Hot Sex
Year:
Tracks: 13
Genetics
Year:
Tracks: 10
Future
Year:
Tracks: 10
Fantasy
Year:
Tracks: 10
Exploration
Year:
Tracks: 13
Ego
Year:
Tracks: 12
Discovery
Year:
Tracks: 9
Alien
Year:
Tracks: 12
Adrenaline
Year:
Tracks: 12
Acceleration
Year:
Tracks: 15
Abyss
Year:
Tracks: 9
Tuesday, 1 July 2008
Markus Schulz
Artist: Markus Schulz
Genre(s):
Trance
Discography:
Progression
Year: 2007
Tracks: 1
Global Dj Broadcast
Year: 2007
Tracks: 10
Global_DJ Broadcast (incl Solar Stone Guestmix)
Year: 2006
Tracks: 1
Global DJ Broadcast (Incl Airwave Guestmix)
Year: 2006
Tracks: 1
Global DJ Broadcast (Incl Harry Lemon Guestmix)
Year: 2005
Tracks: 1
Global DJ Broadcast (Incl Christopher Lawrence Guestmix)
Year: 2005
Tracks: 1
Coldharbour Sessions 2004
Year: 2004
Tracks: 1
Denied: No June Wedding for Depp
Thursday, 19 June 2008
Mark Wahlberg - Wahlberg Hints At Durham Marriage
Actor MARK WAHLBERG has hinted at plans to wed his longtime girlfriend RHEA DURHAM, after referring to the mother of his children as his "future wife" at a New York event on Tuesday (10Jun08).
The couple has been dating since 2001 and has two children together - daughter Ella, four, and Michael, two.
Durham is currently pregnant with their third child - and Wahlberg appears to have marriage on his mind.
Wahlberg was attending the New York premiere of his new movie The Happening when he let slip about his wedding plans.
When asked about his 37th birthday celebrations on 5 June (08), he told People.com, "I had a beautiful day with my kids and my future wife. We went to brunch."
Of their impending arrival, the Boogie Nights star adds, "We're thrilled!"
See Also
Sunday, 8 June 2008
Little Man Tate
Artist: Little Man Tate
Genre(s):
Indie
Rock
Discography:
About What You Know
Year: 2007
Tracks: 11
Man I Hate Your Band
Year: 2006
Tracks: 12
Inexplicably taking their appoint from a saccharine 1991 flick nigh a baby portent leading Jodie Foster, Little Man Tate is a scrappy indie careen band from Sheffield, England. Like their Yorkshire compatriots the Arctic Monkeys, Little Man Tate offers a veddy veddy British ingest on guitar pop. But where the Arctic Monkeys' inspiration lies principally in the Television Personalities (so much so that in 2006 a rumor flew about the Internet that the TVPs' Daniel Treacy was in fact the band's privy ballad maker) and their brand of fractured post-punk, Little Man Tate shares more in common with Blur, the Dentists, and other devotees of the Kinks' blend of tricky tunes and playful lyrics about daily British animation. Singer and rhythm method guitar player Jon Windle, lead guitar player Edward "Maz" Marriot, bassist Ben Surtees, and drummer Dan Fields earlier formed under the list Carousel Moon in 2003, briefly exit through and through the name calling the Moon and Lazy Eye ahead settling on Little Man Tate in 2005. Little Man Tate released their debut single, "The Agent," in March 2006 on their own Yellow Van label. After a irregular self-released single, "What? What You Got," hit the take down reaches of the U.K. Top 40 graph in May of that year, Little Man Tate gestural to V2 Records. V2 released trey more than singles -- "Theater Party at Boothy's," "World, I Hate Your Band," and "Aphrodisiac in Latin" -- with increasing chart success each time, earlier Little Man Tate's debut record album, About What You Know, was released in February 2007.
Saturday, 31 May 2008
Bugz In The Attic
Artist: Bugz In The Attic
Genre(s):
R&B: Soul
Trance
Discography:
Back in the Doghouse
Year: 2006
Tracks: 16
Fabriclive.12
Year: 2003
Tracks: 14
Present Family Factory
Year:
Tracks: 4
Bugz in the Attic is an all-star broken thump gang of DJs and producers based in West London -- a corporate that includes (merely isn't special to) Afronaught, Seiji, Daz-I-Kue, Kaidi Tatham, Mark Force, and Alex Phountzi. Whether lonely, together, or involved in their many sliver projects and one-offs, the members of Bugz in the Attic have likely played a role in well all over half (if non a higher portion) of the releases that can be categorised as broken beat. The group has besides run its possess Co-Op club night and the Bitasweet label as well, which has been an electrical outlet for some of their involvements and interests, including the Phuturistic Dancin' anthologies, Seiji's Remixes compilation, and Dego McFarlane's releases as Cousin Cockroach. In late 2003, they made their contribution to the Fabriclive serial of mix discs.
Thursday, 29 May 2008
Gangsta Pat
Artist: Gangsta Pat
Genre(s):
Rap: Hip-Hop
Discography:
Greatest Hits (His Deadliest Verses)
Year: 2007
Tracks: 15
Deadly Verses
Year: 2006
Tracks: 10
One of the number one Memphis rappers to make the major-label jump, Gangsta Pat never attained the hail or success of swain Memphis pioneers Three 6 Mafia and Eightball & MJG, heretofore he still remains notable for his trailblazing. Pat's career began promisingly when Atlantic gestural him at the dawn of the gangsta rap earned run average and released #1 Suspect (1991) as well as two incidental singles, "I'm tha Gangsta" and "Gangsta's Need Love 2." Like most of Atlantic's other rap releases from the time, Pat's debut made small impact, cursorily going out of print and going the rapper without a transcription contract before long after. Pat returned to the metro the adjacent twelvemonth with Wrap Records, a transitory indie label distributed by Ichiban. Wrap released deuce Pat albums, All About Comin' Up (1992) and Sex, Money & Murder (1994), as well as two several singles, "Gangsta Boogie" and "That Type of Gangsta." Once once again, Pat base small achiever beyond the Atlanta-Memphis axis and hence packed his bags, moving to Power Records for Virulent Verses (1995) and Murderous Lifestyle (1997). These 2 albums showcased a more introspective and mature dash, as Pat sped up his flow à la Bone and darkened his themes à la Three 6 Mafia. Regardless, disdain the cult following he began to earn with these two highly regarded albums, he couldn't render the financial support into national gross revenue, and he touched on to til now some other label, Red Rum. He remained thither for quite a while, cathartic a string of albums commencement with The Story of My Life (1997) that tended to emulate the trends of their various eras. Perhaps as a plea for much-needed promotional material, Pat targeted Three 6 Mafia on his 1999 record album, Tear Yo Club Down, with a pointed dis track.
Live: Wango Tango
Bonecrusher vs Sizzla
Artist: Bonecrusher vs Sizzla
Genre(s):
Drum & Bass
Discography:
Hot Cakes (HC001)
Year: 2005
Tracks: 2
T.I. Previews His Forthcoming LP, Paper Trail, For MTV News
The lyrics made it sound like T.I.'s pen was actually a match.
The King of the South was igniting each track with a viciousness that could well have fans and critics calling his forthcoming Paper Trail LP (due August 12) his best since Urban Legend.
Clearly, Tip's half-year-plus under house arrest wasn't just spent building a huge replica of the Eiffel Tower out of Legos ("It took me two straight days," he said of his work). The MC — who recently said he's not angry that he only came in at #10 on MTV News' "Hottest MCs in the Game" — found escapism in his music and, as he played a handful of tracks from his forthcoming album, at times he sounded better than we've ever heard him.
There are boasts such as "Without the braids, I'm the closest thing to O-Dog" and admonishment of peers like, "What the game need with you? They got me."
Yes, Tip is "back on top like a toupee."
"Turn My Beat Down" feels like a 2008 version of LL Cool J's "Boomin' System." The bass is turned all the way up and the synths inject a futuristic feel to it. Meanwhile, Tip experiments with his voice, but his message is clear: His sounds shake up the city.
"People see me in the street now/ And they wave and tell me to turn my beat down," he raps on the chorus.
"You're a-- in trouble if you pull up next to me/ Beat so loud, you can't hear yourself think," he adds in a verse.
"On Top of the World" is one of the strongest contenders for the album's first single. It stars the newest member of the Grand Hustle fam, B.O.B., on the hook and Kanye West on a guest verse.
"It's just a track of reflection," Tip said of the song. "Looking back to my humble beginnings, just reveling on how far I've come. It's definitely a record that people like Kanye and I ... and even B.O.B. [can relate to]: when you're on the outside looking in and you know you're good. You know you're worthy of being in the game. You know you can compete on a professional level. And once you prove that, it's a level of self-assurance. I can't even describe that."
Tip dances with self-doubt on "My Life, Your Entertainment."
"Kids, you don't wanna be like me/ It's safer to watch me on TV," he says in one line. Later, he threatens to return to a darker space.
"Stayed in trouble just to show these suckers I ain't lost it/ I'll probably do it again/ That's the funny thing about it."
However, he said "not at all" when asked if he'd do some of the things that caused him to face serious trouble before. "It's back there [in my mind]. It's a piece of my mind that I have to be honest with you and share with you. It's a thought. If that thought is not there, I'd never be able to check myself. I'd never be able to say, 'Be careful: You know what could happen.' If I totally discredited the idea, I could never check myself."
"My life, your entertainment," he chants on the hook. "My sorrow, your amusement/ Laugh at my pain and anguish/ So famous I could lose it."
"For a long time, people came home and got they TVs on, looked at the news, just to see how my situation developed and entertain themselves," he explained of the record. "In the meantime, it's my life. People on the computer saying, 'T.I. this, T.I. that. They just said T.I. couldn't do that.' They comment. They don't know nothing about T.I."
The message of "Collect Call" is clear: "Everybody loves you when you ballin'/ Don't nobody want you when you fallin'."
"That song is about when you're on top, everybody wants to ball with you, but when you're not, you probably wouldn't know who to call" explained Tip, who raps on the song, "Everybody talking about me like a n---a just died."
"I'm Illie" is an A-Town anthem that resonates with T.I.'s boasts about being the man in charge.
"Never been f---ed in the game, I'm celibate," he declares. The song's chorus goes, "N---as talk sh--, that's silly/ I run this city, clearly ... Tell that little n---a I'm busy: I'm illaaayy!"
"That's just cats saying they want that old Trap Muzik flow back," he said. "That nonstop, consistent punch-line-and-metaphor wordplay. I gave them that."
T.I. hasn't picked out a first single for the LP yet: He's still recording.
See Also
- Music Impresario and Long-Time Humanitarian Quincy Jones Comments Publicly About China and the Darfur Crisis and His Role as an Artistic Advisor to the Opening Ceremonies of the 2008 Beijing Olympic Games
- Indie prison flicks are breakout trend
- Madonna - Madonna Stunned By Sexual Cleansing Ritual
- Atmarama Das
Jolie daughter's strange pig impersonation
Angelina Jolie’s adopted daughter is pretending to be pregnant with a pig.
The Oscar-winning beauty - who is expecting twins with partner Brad Pitt - says three-year-old Zahara is trying to be like her mummy, and keeps saying the "piggy" inside her is making her crave chocolate brownies.
Angelina - who also has two adopted sons, Maddox, six, and Pax, four, as well as 23-month-old biological daughter Shiloh with Brad - told British breakfast TV show GMTV: “The kids are excited and they are starting to understand about me pregnant. We’ve had it before with Shiloh so they know what’s going on.
“Zahara pretends she’s pregnant too and says she has an animal in her tummy. She says the piggy is making her eat all the chocolate brownies! And Pax says he’s got a baby monkey inside him! So it’s really fun in our house at the moment.”
Angelina also confirmed she is considering delivering her babies in France, because the entire family can speak the language.
She added: "I actually haven't completely decided. We are certainly thinking of France.
"French is a second language in the house, although I'm still learning. My children are starting to speak French, so being in the country is very good for them and their language skills.”
See Also
Blanco Y Negro
Artist: Blanco Y Negro
Genre(s):
Dance
Discography:
Bolero Mix 20 Aniversario CD1
Year: 2006
Tracks: 1
Blanco y Negro Mix 3 (cd2)
Year: 1996
Tracks: 11
Blanco y Negro Mix 3 (cd1)
Year: 1996
Tracks: 9
Nueva carpeta
Year:
Tracks: 5
Blanco y Negro Mix 8 (cd2)
Year:
Tracks: 17
Blanco y Negro Mix 8 (cd1)
Year:
Tracks: 20
Subscribe to:
Posts (Atom)